DMAC vs GPC · $157.4M cap vs P/E 21, rev $23.49B
DiaMedica Therapeutics Inc (DMAC) versus Genuine Parts Co (GPC) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Genuine Parts Co (GPC) is a auto parts company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported GPC revenue for 2024-12-31 was $23.49B. Net income was $904.1M. Revenue was up 1.7% from 2023-12-31 to 2024-12-31. GPC currently screens at market cap $17.60B and trailing P/E 20.7.
DMAC currently screens at market cap $157.4M. GPC currently screens at market cap $17.60B and trailing P/E 20.7.
Not investment advice. Open the DMAC and GPC stock pages for the full models.
Not investment advice.